- $573.52m
- $454.89m
- $418.63m
Brief: MiMedx Q2 Sales USD 87.207 Million Vs. IBES Estimate USD 88.9 Million
MiMedx Group Inc expected to post earnings of 8 cents a share - Earnings Preview
Brief: Cassava Sciences Announces Changes in Executive Leadership
MiMedx Group Inc reports results for the quarter ended in March - Earnings Summary
Brief: MiMedx Q1 Sales USD 84.709 Million Vs. IBES Estimate USD 79.4 Million
MiMedx Group Inc expected to post earnings of 5 cents a share - Earnings Preview
Brief: MiMedx Group Says Pursuing All Available Options To Keep AXIOFILL On Market
Brief: Tela Bio Announces Sale Of Distribution Rights For Wound Care Product To Mimedx
Brief: MIMEDX Appoints Two New Independent Directors
MiMedx Group Inc reports results for the quarter ended in December - Earnings Summary
Brief: MiMedx Q4 Sales USD 86.832 Million Vs. IBES Estimate USD 85.1 Million
MiMedx Group Inc expected to post earnings of 7 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Coherus, Moderna
U.S. STOCKS ON THE MOVE-Rivian, Terran Orbital, Longboard Pharmaceuticals
MiMedx falls on FDA warning letter for its placental-derived Axiofill
MiMedx reports US FDA warning letter for Axiofill, shares drop (updated)
MiMedx says US FDA's warning letter for Axiofill not related to safety
MiMedx Group Inc reports results for the quarter ended in September - Earnings Summary
Brief: MiMedx Q3 Sales USD 81.712 Million Vs. IBES Estimate USD 77.9 Million